EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 508 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Men’s skin cancer rates increase by 50% over decade June 24, 2021 How We’re Working to Help People With Cancer Across the World April 7, 2021 Combined MRI-directed and Standard Biopsy in Men With Elevated PSA and... July 15, 2021 “Scars are Tattoos with Better Stories” July 21, 2021 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΩΟΘΗΚΩΝ Opinion: ‘The UK must be more ambitious than just clearing the... 10 Ways to Brave Cancer Treatment: Tips from a Survivor Immunotherapy Combination That Targets TIGIT Receptor Shows Promise in Non-Small Cell...
